Navigation Links
ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
Date:9/26/2007

d by antibodies that react specifically with CXCR7. The analyses of the human tumors verified that CXCR7 is highly expressed by both the malignant tumor cells and by the tumor-associated blood vessels in the tumor mass, but not found on healthy cells or normal vasculature outside of the tumor mass. These findings were further extended to multiple tumor types, and researchers believe that CXCR7's activity in cancer may be important in a broad range of malignancies. Observations around CXCR7's role in tumor vasculature formation were further evidenced in knockout experiments in a zebrafish model, strongly suggesting that CXCR7 is central to the formation of new blood vessels during development (a process known to resemble aspects of new blood vessel formation in tumors). Taken together, these observations show that CXCR7 may be central to the rapid formation of new blood vessels, a process known as angiogenesis, necessary for tumor growth.

"Drugs targeting tumor angiogenesis represent an important mode of therapy in modern cancer treatment regimens," said Dr. Schall. "Our work shows that CXCR7 may provide an entirely new and powerful target in the approach to future oncology therapy."

EnabaLink Identifies Potent Classes of Chemokine-Based Therapeutics

The data published today result from ChemoCentryx's extensive chemokine drug discovery capabilities and insights into chemokine system biology. CXCR7 is a chemokine receptor that was 'deorphanized' (a function was discovered for the protein encoded by a gene of previously unknown function) at ChemoCentryx through the company's proprietary EnabaLink Drug Discovery(R) engine. Leveraging the EnabaLink suite of technologies, ChemoCentryx is uniquely able to identify highly specific product candidates including orally-active small molecules that bind with high affinity to a specific chemokine receptor. ChemoCentryx has leveraged its EnabaLink Drug Discovery engine for the identification and optimization of e
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System
2. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
3. Detecting Gastrin-Releasing Peptide Receptor by in situ PCR on Archived Tissue
4. pFB-ERV: Retroviral Delivery of the Ecdysone Receptor Proteins
5. Gene-Specific Primers for NMDA Receptor Subunits
6. TKB1 Cells Identify Receptor Tyrosine Kinase Interacting Proteins
7. Quantification of the Purinergic Receptor P2X3 using ICAT and Orthogonal 2D LC-MS/MS with an Ion Trap Mass Spectrometer
8. Isolation of Low Molecular Weight Digestion Products of the Human Platelet Thromboxane A2 Receptor, Rev A
9. Performance of Ad-A-Gene EGFP-Glucocorticoid Receptor (EGFP-GCCR): an adenoviral vector gene delivery system
10. The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System
11. The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ) ... Chief Financial Officer has resigned.  The Company has hired ... who retired in December 2014, as full time interim ... successor.     Andy Ashworth began his ... a smooth transition.  Andy was the Company,s CFO from ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... and supplier, announces the launch of their 2nd generation cell therapy POD® design. ... miniPOD CT, but it also represents a new POD® design. , “G-CON ...
(Date:7/29/2015)...  AmnioChor Inc., an early stage biotech startup based ... announce that the Musculoskeletal Transplant Foundation of ... their seed round of development of the proprietary AmnioCept™ ... AmnioChor,s technology allows cryopreservation of the amniotic ... living within those tissues. Amnion is a well-established source ...
(Date:7/29/2015)... , July 29, 2015  Indivior PLC (LON: INDV) ... naloxone nasal spray was accepted and received Priority Review ... the treatment of opioid overdose. This naloxone nasal spray ... formulated for optimal absorption into the nasal mucosa. 1 ... training so individuals may be better equipped to help ...
Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5
... , WARSAW, Ind., Oct. 28 Zimmer Holdings, Inc. ... OMeGA Medical Grants Association LLC (OMeGA) has chosen its ... third party administrator for graduate medical education to which ... for the 2009-2010 academic year. , OMeGA received more ...
... PLYMOUTH MEETING, PA., Oct. 28 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone,Corporation ... today announced,the appointment of Daniel P. Harrington to the ... Mr. Harrington brings more than thirty years of management ... traded,companies. Since 1995, he has been President and CEO ...
... Oct. 28 GenVec, Inc. (Nasdaq: GNVC ) announced ... ended September 30, 2009 on Thursday, November 5, 2009 after ... a.m. EST on Friday, November 6, 2009 to discuss the ... ) , To listen to the live conference ...
Cached Biology Technology:Zimmer Holdings Announces OMeGA Graduate Medical Education Grant Recipients 2Zimmer Holdings Announces OMeGA Graduate Medical Education Grant Recipients 3Zimmer Holdings Announces OMeGA Graduate Medical Education Grant Recipients 4BMP Sunstone Appoints Daniel Harrington to Board of Directors 2GenVec Announces Third Quarter 2009 Results Conference Call 2
(Date:7/9/2015)... Calif. , July 9, 2015  Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... Thursday, July 30, 2015 after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
(Date:7/8/2015)... NEW YORK , July 8, 2015 ... cancer globally, and the fourth most fatal, with a ... year. The poor prognosis of pancreatic cancer patients has ... to treatment, which is not being met by the ... contains an array of products with varying molecule types ...
(Date:7/7/2015)... 2015 Research and ... of the "Capacitive Fingerprint Sensors Patent Landscape" ... this date, fingerprint sensing technology is the most ... are well developed. This patent landscape focuses on ... The domain of capacitive fingerprint sensors is closely ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... than a holiday favorite, given their remarkable nutritional and health ... international journal Advances in Nutrition provides ... and not just a side dish. The review authors conclude ... the incidence of certain infections, improve heart health and temper ...
... Diseases affecting the kidneys represent a major and unsolved ... they are damaged by disease, highlighting the urgent need ... Now, a team of researchers led by scientists ... a novel platform to study kidney diseases, opening new ...
... Acta Obstetricia et Gynecologica Scandinavica , a journal of ... indicate that human error is the most common cause ... of clinical skills, and failure to obtain senior medical ... claims following birth asphyxia. In Norway there ...
Cached Biology News:Cranberries have health-promoting properties, new expert review reveals 2Cranberries have health-promoting properties, new expert review reveals 3Salk scientists for the first time generate 'mini-kidney' structures from human stem cells 2Salk scientists for the first time generate 'mini-kidney' structures from human stem cells 3Human error most common cause of birth asphyxia 2
... intended for use as a wash buffer for ... Fluid is useful for transportation of specimens (such ... studies. Samples may remain in Transport Fluid ... Michels Transport Fluid is not a fixative ...
... Systems provide rapid, precise localization of ... frozen or paraffin-embedded tissue, cytospins and ... facilitate double or triple labeleing experiments, ... with primary antibodies of different animal ...
... covers can be used with ... covers for stacking of covered ... for use with automated systems ... and non-ridged, are available for ...
SYBR Green Nucleic Acid Dye...
Biology Products: